Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab

Leukemia volume 19, pages 2005–2008 (2005)Cite this article

TO THE EDITOR

T-cell large granular lymphocyte leukemia (T-LGL) is a lymphoproliferative disorder characterized by a persistent increase of peripheral blood large granular lymphocytes and an indolent clinical course with moderate splenomegaly, rheumatoid arthritis and neutropenia.1 Most cases have a CD3+, TCRαβ+, CD4−, CD8+ phenotype, but rare variants may express CD3 and TCRγδ epitopes. CD56 and CD57 are variably expressed. Rearrangements of T-cell receptor genes indicate the clonal nature of the disease. In cases requiring therapy, initial treatment consists of cyclosporin A (CSA), methotrexate (MTX) or corticosteroids.2 Treatment indications include severe neutropenia, anemia, splenomegaly and clinical symptoms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chan WC, Catovsky D, Foucar K, Montserrat E . T-celll large lymphocyte leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). The WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp 197–198.

    Google Scholar 

  2. Burks EJ, Loughran Jr TP . Perspectives in the treatment of LGL leukemia. Leuk Res 2005; 29: 123–125.

    Article  Google Scholar 

  3. Kwong YL, Wong KF . Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998; 51: 672–675.

    Article  CAS  Google Scholar 

  4. Xiuqing R, Liebman HA . Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123: 278–281.

    Article  Google Scholar 

  5. Osuji N, Matutes E, Wotherspoon A, Catovsky D . Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res 2005; 29: 225–228.

    Article  CAS  Google Scholar 

  6. Lundin J, Porwit-MacDonald A, Rossman ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphatic leukemia. Leukemia 2004; 18: 484–490.

    Article  CAS  Google Scholar 

  7. Laurenti L, Piccioni P, Tarnani M, Chiusolo P, Piccirillo N, Rumi C et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphatic leukemia. Leukemia 2005; 19: 153–154.

    Article  CAS  Google Scholar 

  8. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

    C Schützinger, A Gaiger, L Öhler, F Reinhard & U Jäger

  2. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

    R Thalhammer, R Fritsche-Polanz & I Schwarzinger

  3. Division of Pathology, Krankenhaus Lainz, Medical University of Vienna, Vienna, Austria

    M Vesely

  4. Department of Pathology, Medical University of Vienna, Vienna, Austria

    I Simonitsch-Klupp

Authors
  1. C Schützinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Gaiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Thalhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Vesely
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Fritsche-Polanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Schwarzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Öhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Simonitsch-Klupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Reinhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. U Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Jäger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schützinger, C., Gaiger, A., Thalhammer, R. et al. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 19, 2005–2008 (2005). https://doi.org/10.1038/sj.leu.2403956

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403956

This article is cited by

Search

Advanced search

Quick links